Archive for the ‘Gene Therapy Research’ Category

Christiana Care: Cancer Genetic Counseling
Knowing the risks for cancer in your family may help you to avoid cancer or to find it early, when it is most curable. The genetic risk assessment program at Christiana Care #39;s Helen F. Graham Cancer Center can help identify your risks for hereditary cancer based on family history and genetics, as well as additional personal and environmental factors.

By: ContentDelaware

See more here:
Christiana Care: Cancer Genetic Counseling - Video

Public release date: 13-Jan-2013 [ | E-mail | Share ]

Contact: Kathy Beal kbeal@acmg.net 301-238-4582 American College of Medical Genetics

Health, science and genetics reporters are invited to register now for the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, March 19-23, 2013 at the Phoenix Convention Center. From Genetic Testing to Whole Genome/Exome Sequencing, the focus of the ACMG Meeting is on the actual practice of genetics and genomics in healthcare today and in the future. The conference will showcase the latest breakthroughs in genetics research and its practical applications to medical practice and public health. The ACMG Annual Meeting attracts medical and scientific leaders from around the world who are working to apply research in genetics and the human genome to the diagnosis, management, treatment and prevention of genetic conditions and rare and common diseases.

From the cytogenomics of cancer to neurogenetics; from noninvasive prenatal diagnosis to whole genome analysis; and from medical reimbursement issues to next generation sequencing, reporters will hear about the latest research; have the opportunity to interact with doctors, laboratory professionals and genetic counselors about what is happening right now in genetics and genomics; and view the latest products available in the extensive exhibit hall.

Topics range from common conditions to rare diseases. Sessions include information of interest to the general public, to health professionals and to the industry/trade.

The ACMG Meeting is the genetics meeting most focused on the practical applications of genetic discoveries in a clinical setting.

###

To see the complete program, visit http://www.acmgmeeting.net.

Photo/TV Opportunity: The ACMG Foundation will present bicycles to local children with rare genetic diseases at the Annual Day of Caring at the Annual Meeting in Phoenix.

To receive a complimentary media registration, contact Kathy Ridgely Beal, MBA at kbeal@acmg.net for the Press Registration Access Code.

Read more here:
ACMG 2013 Clinical Genetics Meeting -- Complimentary press registration is now open

BOCA RATON, FL--(Marketwire - Jan 14, 2013) - Atossa Genetics ( NASDAQ : ATOS ), the Breast Health Company, based in Seattle, Washington, and Clarity Women's Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida, announced today the launch of the ForeCYTE Breast Health Test at Clarity's national sales meeting, held on January 10-11th, 2013, in Boca Raton, Florida. The patented ForeCYTE Breast Health Test is designed for the early detection of precancerous breast conditions and the determination of the future risk of breast cancer, using a clinically validated algorithm including family history, personal reproductive history and breast cytopathology. The ForeCYTE Test, which uses the patented, FDA-cleared MASCT Breast Health System to painlessly collect a tiny sample of nipple ductal fluid, is designed to be performed at the point of care in a non-invasive and highly sensitive manner.

"Clarity Women's Health brings tremendous relationships with its clients driven by highly skilled technical support and customer service teams. I believe we have a strong national launch strategy working with the Clarity team and we anticipate rapid adoption as physicians' access to the ForeCYTE test is expanded," said Chris Destro, Vice President of Sales and Marketing, Atossa Genetics, Inc. "The passion and commitment of the entire team at Clarity Women's Health to make a difference in the current paradigm of breast health is palpable."

"The ForeCYTE Breast Health Test is the cornerstone of our new division, Clarity Women's Health," stated Daniel Lger, Vice President of Sales and Marketing, Diagnostic Test Group, LLC. "This product is targeted for over 110 million women between the ages of 18 and 73 in the U.S. who can now obtain a simple test in their physician's office and learn their future risk of breast cancer up to eight years before mammography can pick it up. This kind of advanced information was created for cervical cancer by the Pap smear and was responsible for the 75% reduction in the incidence of cervical cancer. The ForeCYTE Breast Health Test has the potential to do the same for breast cancer."

For more information, please click the following link to view a video interview with Christopher Destro, VP of Sales and Marketing of Atossa genetics discussing aspects of this press release in more detail: http://client.irwebkit.com/AtossaGenetics/media. You may also sign up to receive automatic email News Alert updates there.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

About Clarity Women's Health

Clarity Women's Health is a division of Diagnostic Test Group, LLC in Boca Raton, FL, and is a sales, marketing and branding company focused on the sale and distribution of its own Clarity brand of rapid and diagnostic tests, molecular tests, and diagnostic equipment utilized in physicians' offices, clinics, labs, urgent care centers and hospitals. DTG offers one of the largest lines of diagnostic tests in the industry supported by its own national sales force combined with in-house 24 hour customer service and tech support. Clarity products are available at most of the recognized national distributors. The ForeCYTE Breast Health System will form the cornerstone of its newly created division, Clarity Women's Health.

Original post:
Atossa Genetics and Clarity Women's Health Announce U.S. Launch of the ForeCYTE Breast Health Test

Genetic engineering human-animal genetic hybrid or chimera
Genetic engineering human-animal genetic hybrid or chimera Trans-Humanism Mixing Human DNA with Animal DNA. Tom Horn WARNING of disaster BREAKING NEWS ALERT WARNING TO HUMAN RACE human-animal genetic hybrid or chimeras full grown thousands of labs worldwide with animal human experiments this is sick and funded by the world Governments. Do your research what the UN is preparing to do between now and 2025 worldwide. We are in the end times last days the medical field is playing god DANGEREOUS times we are living Part Human part animal genetic hybrids A parahuman or para-human is a human-animal Genetic engineering human-animal genetic hybrid or chimera hybrid or chimera. Scientists have done extensive research into the mixing of genes or cells from different species, eg adding human (and other animal) genes to bacteria and farm animals to mass-produce insulin and spider silk proteins, and introducing human cells into mouse embryos. Parahumans have been referred to as "human-animal hybrids" in a vernacular sense that also encompasses human-animal chimeras. The term parahuman is not used in scientific publications. The term is sometimes used to sensationalize research that involves mixing biological materials from humans and other species. It was used in a National Geographic article to describe an experiment in 2003, during which Chinese scientists at the Shanghai Second Medical University successfully fused human cells with rabbit eggs. According to Daily Mail, as of 2011 ...

By: u2bheavenbound

Follow this link:
Genetic engineering human-animal genetic hybrid or chimera - Video

The Youth Pill
Science for the Public, September 10, 2010. David Stipp, author of The Youth Pill: Scientists at the Brink of an Anti-Aging Revolution. discusses how scientific and medical researchers are addressing the issue of aging. As modern populations live longer, it is necessary to understand both the aging process itself and the potential for greater longevity with good health. Mr. Stipp makes a sharp distinction between bogus claims of an easy way to obtain longevity and the very serious research in genetics and other fields suggesting the possibility of extending productive life. He offers a very clear analysis of the scientific data on aging, and he argues the case for more research and better public information on this issue.

By: scienceforpublic

View post:
The Youth Pill - Video

Minecraft Lets Play - Episode 25 - MINECRAFT COW GENETICS GONE WRONG
Please leave a like! It helps out a lot! 🙂 Minecraft, The game where cows have sex and pop out a horrible genetically wrong cow.. Enjoy!! 😀 Facebook Page: http://www.facebook.com

By: JJGaming000

See more here:
Minecraft Lets Play - Episode 25 - MINECRAFT COW GENETICS GONE WRONG - Video

Sentinels training 2012JAN11 [uncut]
ETHOS outfit ( ethosoutfit.forumsmotion.com ) Shortcuts: 11:20 mdash; Briefing 22:05 mdash; Mission #1 (Aurora materials lab) 26:50 mdash; Mission #2 (Apex genetics) 36:25 mdash; Mission #3 (Saerro listening post) 49:26 mdash; Side mission (C @ Saerro listening post) 58:00 mdash; Mission #4 (Palos solar array) 59:23 mdash; Tank push 1:03:00 mdash; Lib push 1:13:13 mdash; Mission #5 (Spec-ops training camp) 1:19:38 mdash; Mission #6 (Lost end outlook) 1:26:40 mdash; Mission #7 (Red ridge communications) 1:43:20 mdash; Training summary 1:48:35 mdash; ROBOCaster #39;discussion #39;

By: #1040; #1083; #1077; #1082; #1089; #1077; #1081; #1050; #1080; #1088; #1100; #1103; #1085; #1086; #1074;

See the rest here:
Sentinels training 2012JAN11 [uncut] - Video

Published: 1/12/2013 3:25 PM | Last update: 1/12/2013 11:53 PM By Ken Stephens - The Hutchinson News - kstephens@hutchnews.com AgReliant Genetics finalized contracts last week for a corn breeding research facility and nursery near Mount Hope, Harlan Priddle, executive director of the K-96 Corridor Development Association announced at the organization's annual meeting Friday.

AgReliant Genetics, headquartered in Indiana, has purchased and will remodel two metal buildings just south of K-96 and two miles west of Mount Hope for the seed research station. Mike Popelka, the station manager and corn breeder, said construction work would begin within the month and hopefully be finished in March.

Initially the facility will employ Popelka and Bryan Unruh, the yield trial manager. Full-time employment is expected to grow to three or four people over the next couple of years, but AgReliant also will employ about 25 part-time seasonal workers to help with hand-pollinating the corn and other tasks, Popelka said.

The research station will develop new hybrid varieties of yellow No. 2 corn to be grown in the western corn belt of Kansas, southern Nebraska, southwest Iowa and western Missouri, Popelka said. The No. 2 corn is used primarily for cattle feed.

In a press release, AgReliant said the southwest section of the corn belt has been a key source of growth for the company and the goal of the station would be to continue the development of top-performing hybrids for irrigated and dry land farming.

The seed research station will be one of 11 operated by AgReliant in North America but the first in Kansas. AgReliant's other research stations are in Nebraska, Iowa, Minnesota, Illinois, Indiana, Michigan and Ontario, Canada.

In recent weeks the company obtained a special use permit from Reno County for the research station. But there were details that still needed to be ironed out before AgReliant was ready to confirm its plans in Reno County.

Popelka received a Bachelor of Science degree from Kansas State University and doctorate in plant breeding from Purdue University. Unruh received his Master of Science degree in crop production from Kansas State.

Reno County Commission Chairman James Schlickau, a member of the K-96 association's board of directors, said he was excited that the seed research station was coming to southwest Reno County.

"I think it's a great use of the land and buildings out there," he said.

See the original post here:
Corn genetics facility coming to Mount Hope

gene therapy strategies to offensive biowarfare
source-thayer.dartmouth.edu

By: jon clem

Read the original here:
gene therapy strategies to offensive biowarfare - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dd7jnv/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Companies Mentioned

Follow this link:
Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/t5whmr/cardiovascular) has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their offering.

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.

Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.

The cardiovascular drug delivery markets are estimated for the years 2011 to 2021 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Selected 80 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 78 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 27 tables and 7 figures.

Key Topics Covered:

Executive Summary

See the article here:
Research and Markets: Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cvngvs/cytogenetics) has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering.

This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics. Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879. The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.

FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described.

Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects.

The chapter on markets provides a global perspective of the cytogenetics business in the major markets: US, Western Europe (including France, Germany, Italy, Spain, and the UK), and Japan. The total figures for the market are also broken out according to the technologies and major disease areas in which they are applied. Markets figure are given for the year 2012 and estimates are made for the years 2017 and 2022. Advantages and limitations of various technologies have been pointed out throughout the report but this chapter includes SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis of some of the competing technologies including the following: conventional FISH, innovative FISH technologies, PCR-based assays, and single molecule imaging. Unfulfilled needs in cytogenetics market are depicted graphically. Among various technologies, FISH is most advanced and less opportunities for further development than single molecule detection, which is in infancy and has more future potential.

The report includes summary profiles of 70 companies relevant to cytogenetics along with their 68 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified.The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography.

Key Topics Covered:

Executive Summary

1. Introduction

Read this article:
Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013

Comedian Explains Genetic Engineering To A Heckler In 21 Seconds
How to explain genetic engineering at the IQ of a heckler in 21 seconds.

By: Jay-Ram Rajendra

Read more:
Comedian Explains Genetic Engineering To A Heckler In 21 Seconds - Video

Become a Genetic Engineer
Break-through in the cutting edge field of genetic engineering. Avanse provides you education loans to pursue your interests in the best universities in the world.

By: AvanseEducationLoans

Go here to read the rest:
Become a Genetic Engineer - Video

Public release date: 10-Jan-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 10, 2013Stem cells can be grown on biocompatible scaffolds to form complex tissues such as bone, cartilage, and muscle for repair and regeneration of damaged or diseased tissue. However, to function properly, the cells must often grow in a specific pattern or alignment. An innovative method for creating a stretched polymer scaffold that can support complex tissue architectures is described in an article in Tissue Engineering, Part C, Methods, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Tissue Engineering, Part C, Methods website.

Zu-yong Wang and a team of researchers from National University of Singapore, Nanyang Technological University, KK Women's and Children's Hospital, and Duke-NUS Graduate Medical School, in Singapore, developed a reproducible method that involves stretching a polymer thin film to produce scaffolds that can support the growth of human mesenchymal stem cells. The stretching process creates orientated 3-dimensional micro-grooves on the surface of the films, and these formations promote consistent alignment and elongation of stem cells as they grow and develop into tissues on and around the resorbable scaffold.

The authors present their work in the article, "Biomimetic 3D anisotropic geometries by uniaxial stretch of poly(?-caprolactone) films for mesenchymal stem cell proliferation, alignment and myogenic differentiation."

"The researchers developed a very elegant method to promote cell behavior," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands.

###

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly in print and online in three parts: Part A--the flagship journal; Part BReviews; and Part CMethods. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the Official Journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Continue reading here:
3-D biomimetic scaffolds support regeneration of complex tissues from stem cells

Researcher Lee Hadwiger has an idea that he believes could play a major role in the future of world hunger.

Hadwiger, a longtime professor and plant pathologist at WSU, published an article in the peer-reviewed journal Phytopathology this month explaining his idea of how to trigger a plants natural defense mechanism to viruses, bacteria, fungi and other pathogens in its environment.

The defense response comes from a common trait called non-host resistance (NHR). Without the trait, plants would easily succumb to the numerous pathogens all around them. Courtesy of Lee HadwigerLee Hadwiger conducted research for plant immune system defense mechanisms.

If you just take Palouse soil and put a plant in there, its got a lot of fungi and bacteria already in there that the plant has to deal with, he said. Some of the newer crops, like chickpeas, seem to be more susceptible to a lot of stuff in the soil, so its a real problem.

Hadwigers article details his work with pea pods, showing that certain fungal DNase enzymes proteins that spur changes within DNA can activate the defense response before the diseases take hold and destroy the plants.

The concept could save countless yields of crops from destruction each year, he said.

Hadwiger worked with his colleague Jim Polashock, a New Jersey-based plant pathologist with the U.S. Department of Agricultures Agricultural Research Service, to demonstrate how to trigger the NHR defense response in pea plants by using bakers yeast. One of Hadwigers students recently activated the defense response in a tobacco plant with a fungal DNase enzyme, as well.

Most people didnt realize that these DNases could trigger this response and that they were present in all of the fungi, Hadwiger said.

The prevailing methods of disease control in agriculture target specific diseases, but the pathogens evolve to find ways around the resistance in a matter of about seven years, Hadwiger said. However, he sees triggering the NHR defense as more of a permanent solution.

But Hadwigers idea needs to conquer one big hurdle before it can achieve widespread adoption in the agricultural community: the public must become more comfortable with consuming genetically modified food.

View post:
Genetic modifications could strengthen plants

BERKELEY A simple, precise and inexpensive method for cutting DNA to insert genes into human cells could transform genetic medicine, making routine what now are expensive, complicated and rare procedures for replacing defective genes in order to fix genetic disease or even cure AIDS.

Discovered last year by Jennifer Doudna and Martin Jinek of the Howard Hughes Medical Institute and University of California, Berkeley, and Emmanuelle Charpentier of the Laboratory for Molecular Infection Medicine-Sweden, the technique was labeled a "tour de force" in a 2012 review in the journal Nature Biotechnology.

That review was based solely on the team's June 28, 2012, Science paper, in which the researchers described a new method of precisely targeting and cutting DNA in bacteria.

Two new papers published last week in the journal Science Express demonstrate that the technique also works in human cells. A paper by Doudna and her team reporting similarly successful results in human cells has been accepted for publication by the new open-access journal eLife.

"The ability to modify specific elements of an organism's genes has been essential to advance our understanding of biology, including human health," said Doudna, a professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute Investigator at UC Berkeley. "However, the techniques for making these modifications in animals and humans have been a huge bottleneck in both research and the development of human therapeutics.

"This is going to remove a major bottleneck in the field, because it means that essentially anybody can use this kind of genome editing or reprogramming to introduce genetic changes into mammalian or, quite likely, other eukaryotic systems."

"I think this is going to be a real hit," said George Church, professor of genetics at Harvard Medical School and principal author of one of the Science Express papers. "There are going to be a lot of people practicing this method because it is easier and about 100 times more compact than other techniques."

"Based on the feedback we've received, it's possible that this technique will completely revolutionize genome engineering in animals and plants," said Doudna, who also holds an appointment at Lawrence Berkeley National Laboratory. "It's easy to program and could potentially be as powerful as the Polymerase Chain Reaction (PCR)."

The latter technique made it easy to generate millions of copies of small pieces of DNA and permanently altered biological research and medical genetics.

Two developments - zinc-finger nucleases and TALEN (Transcription Activator-Like Effector Nucleases) proteins have gotten a lot of attention recently, including being together named one of the top 10 scientific breakthroughs of 2012 by Science magazine. The magazine labeled them "cruise missiles" because both techniques allow researchers to home in on a particular part of a genome and snip the double-stranded DNA there and there only.

Follow this link:
DNA snipping technique could transform gene therapy

Fetal DNA circulating in a pregnant mothers blood can be used to detect a wide variety of genetic abnormalities before birth, opening the door for noninvasive testing for more conditions.

By sequencing DNA that escapes into womens bloodstreams, scientists were able to detect disease-causing mutations that are now normally found by piercing a mothers womb with a needle to get amniotic fluid, according to a study in the American Journal of Human Genetics.

Amniocentesis, the standard procedure for prenatally testing for genetic conditions such as Down syndrome, carries a low risk of miscarriage. Obtaining DNA from a blood sample from the mother carries virtually no risk, and may enable doctors to expand their reach and accuracy as they look for genetic disease, said Cynthia Morton, a Harvard Medical School geneticist who performs prenatal tests at Brigham & Womens Hospital in Boston.

This could largely replace invasive testing, she said in a telephone interview, and, no doubt, is an exciting next step in the future of prenatal testing.

The study was done by scientists at Tufts Medical Center in Boston and Verinata Health Inc. in Redwood City, California. Illumina Inc. (ILMN), the biggest maker of DNA sequencers, said this week that it will buy Verinata for $350 million plus as much as $100 million in milestone payments through 2015.

Interest in sequencing fetuses and newborns is increasing as more laboratories are showing that DNA analysis can quickly diagnose rare diseases that once took years to unravel. The U.S. National Human Genome Research Institute and the National Institute of Child Health and Newborn Development have set aside $25 million to study questions related to sequencing newborns over the next five years.

Verinata and other companies already offer blood tests that analyze circulating fetal DNA to diagnose Down syndrome, a genetic condition in which a baby is born with three copies of chromosome 21, instead of the normal two. The same tests can detect other conditions in which the fetus has too many copies of certain chromosomes, which are the packages that hold large amounts of DNA within the cells nucleus.

In the study published today, the team showed that they can detect far smaller genetic flaws that affect just portions of chromosomes. The test was able to find abnormalities involving as little as 100 kilobases of DNA, a fraction of the millions of chemical bases that each chromosome normally contains.

The price of sequencing DNA is falling quickly, and as it does, the scientists are using the procedure to replace and expand on established medical tests. In a study released yesterday in the journal Science Translational Medicine, for example, researchers showed that DNA analysis of the Pap smear for cervical cancer can also identify malignancies of the ovaries and endometrium.

Currently, doctors who believe a fetus may harbor a genetic condition analyze chromosomes and DNA taken by amniocentesis.

Link:
DNA in Mother’s Blood Can Spot Genetic Mutations in Fetus

Café Scientifique Topic 27: Scientific Construction of Race
How much do you really know about the geographic, racial and ethnic origins of your personal ancestors? How old were you when you first learned about race? Come join us in a fascinating conversation about the evolution of race and what scientists say about race with Mike Lange, Associate Professor of Anthropology, Champlain College and John Burke, Professor, Microbiology Molecular Genetics, UVM. View the exhibit Race: Are We So Different? during social time.

By: echovermont

Read more here:
Café Scientifique Topic 27: Scientific Construction of Race - Video

Podcast- Genetics PBL
I created this video with the YouTube Video Editor (www.youtube.com

By: vamosrramos

Read more:
Podcast- Genetics PBL - Video

Food and Fuel for the 21st Century with Stephen Mayfield -- Founders #39; Symposium 2012
(Visit: http://www.uctv.tv The Director for the San Diego Center for Algae Biotechnology shares his enthusiasm for the potential of algae in developing food and fuel. Stephen Mayfield #39;s research focuses on the molecular genetics of green algae and on the production of high value recombinant proteins and biofuel molecules. His talk was presented as part of the 2012 Founders #39;s Symposium at UC San Diego. Series: "UC San Diego Founders #39; Day" [Science] [Show ID: 24693]

By: UCtelevision

Link:
Food and Fuel for the 21st Century with Stephen Mayfield -- Founders' Symposium 2012 - Video

Weight Loss Journey Transformation Before and After Time Lapse
#9658; #9658;goo.gl #9658; #9658;goo.gl #9658; #9658;goo.gl Watch My Full Video http://www.youtube.com Weight Loss Journey Transformation Before and After Time Lapse them seem to target thyroid specifically. I will go back on and look for the ones mentioned here though. Citations may include links to full-text content from PubMed Central and publisher web sites. PubChem Substance All Chemicals Bioassays Resources. DNA RNA BLAST Basic Local Alignment Search Tool . Data Software BLAST Basic Local Alignment Search Tool . Splign Vector Alignment Search Tool VAST . Conserved Domain Search Service CD Search . Database of Genotypes and Phenotypes dbGaP . Map Viewer Online Mendelian Inheritance in Man OMIM . Bookshelf Database of Genotypes and Phenotypes dbGaP . RefSeqGene All Genetics Medicine Resources. Genomes Maps Database of Genomic Structural Variation dbVar . Homology BLAST Basic Local Alignment Search Tool . BLAST Link BLink Conserved Domain Database CDD . Conserved Domain Search Service CD Search . Protein Clusters All Homology Resources. Sequence Analysis BLAST Basic Local Alignment Search Tool . BLAST Link BLink Conserved Domain Search Service CD Search . Variation Database of Genomic Structural Variation dbVar . Database of Single Nucleotide Polymorphisms dbSNP . But y,ou s_hould tr,y the alternative ,m+edication! Large a mount of fa,t food -lack #39; of activity i #39;n your lif e can caus #39;e ob_esity. Total Price: Depends on the product properties you select. Place of Origin: Guangdong China ...

By: UltraSexyBody

Read more:
Weight Loss Journey Transformation Before and After Time Lapse - Video

Genetics at Billies 2

By: Gerard Anderson

Link:
Genetics at Billies 2 - Video

Melungeon DNA: Melungeon pictures
Melungeon pictures photos images. Melungeon DNA: Operation Truth Melungeon truths series that tells the truth about the melungeon, alot of misinformation has been told about the melungeon, this video is part of a series that exposes the truth about the genetics of the melungeon, The Melungeon are from newman #39;s ridge in tennesse, the source melungeon are vardy collins and shepard gibson, other melungeon are the denham and mullins and goins, melungeon history is a good site to find truthful information on the melungeon people. Joanne has spent many years documenting melungeon people. according to wikipedia, Melungeon is a term traditionally applied to one of a number of "tri-racial isolate" groups of the Southeastern United States, Melungeon were often referred to as of Portuguese or Native American origin.The melungeon dna series exposes the misinformation on the melungeon people and proves the melungeon ancestors was who they said they was. Thru DNA is was showed the melungeon people have portuguesse ancestry. Many people says dna does not lie and that is exactly what was proven thru DNA tests on the melungeon people. It has been a long time since media has heard the acutal newmans ridge melungeons voice themself, now is the time the melungeon people of the ridge tell the truth about their dna results and what those dna results actually mean. In this Melungeon DNA Series, we break down different aspects of the Melungeon people to separate non melungeon from actual ...

By: Monasukapanough

Link:
Melungeon DNA: Melungeon pictures - Video

FINDING YOUR ROOTS | PBS America
FINDING YOUR ROOTS - premieres Sundays at 8pm from 24 February 2013 PBS America - Sky 166 / Virgin Media 243 / pbsamerica.co.uk PBS America - the new channel from America #39;s Public Broadcasting Service (PBS) - brings British audiences Finding Your Roots, a brand new 10-part series that explores race, culture and identity through genealogy and genetics. Having launched America #39;s current trend of ancestry-related TV shows back in 2006 with African American Lives, Professor Gates says this, his 12th television series, "gets into the DNA of American culture". In each hour-long episode, he takes viewers along for the journey with one celebrity group bound together by an intimate, sometimes hidden, link; trekking through layers of ancestral history, uncovering secrets and surprises of their family trees and sharing life-altering discoveries. This exciting new format, which harnesses new and powerful DNA analysis techniques to unlock lost branches of family trees, launches with an episode featuring actor Samuel L. Jackson, former Secretary of State Condoleezza Rice and Brown University President Ruth Simmons. Each has climbed to the pinnacle of their profession, yet each started life as a second class citizen in the Jim Crow south. In this launch episode, Gates uses DNA analysis to investigate where each of them come from in Africa, and who the white men are in their family trees. Guest groupings include award-winning husband-and-wife actors Kevin Bacon and Kyra Sedgwick, who ...

By: PBSukchannel

Excerpt from:
FINDING YOUR ROOTS | PBS America - Video